




PHARMACEUTICAL 2021

Aptevo Therapeutics Inc.
Rank 275 of 402





PHARMACEUTICAL 2021

Aptevo Therapeutics Inc.
Rank 275 of 402



The relative strengths and weaknesses of Aptevo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aptevo Therapeutics Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Aptevo Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is 24%, being 24% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	47,264
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,539
Liabilities, Non-Current	2,360
Other Assets	3,468
Other Compr. Net Income	0
Other Expenses	1,325
Other Liabilities	20,054
Other Net Income	11,069
Other Revenues	4,309
Property and Equipment	2,815
Research and Development	17,852
Selling, General and Administrative Expense	13,951

Output Variable	Value in 1000 USD
Assets	53,547
Liabilities	36,953
Expenses	33,128
Revenues	4,309
Stockholders Equity	16,594
Net Income	-17,750
Comprehensive Net Income	-17,750
Economic Capital Ratio	24%